



*FW*

CERTIFICATE OF MAILING  
UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313 on

17 January 2007  
HUESCHEN AND SAGE

Michelle M. C.  
Dated: 17 January 2007

MERZ 36 US

\* \* \* \* \*

Applicant : Hans-Joerg MOEBIUS  
Serial No. : 10/691,895  
Filed : October 23, 2003  
Title : COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS  
Art Unit : 1623  
Examiner : Eric OLSON, Esq.

\* \* \* \* \*

Honorable Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313

RESPONSE AND ELECTION UNDER 37 CFR §§ 1.111 AND 1.142

AND

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR  
§§ 1.97 AND 1.98

Sir:

Responsive to the Office Action, a Restriction Requirement, dated July 25, 2006, as

**to which the period for response has been extended by five (5) months by**

01/22/2007 JBALINAN 00000054 10691895

01 FC:1255 2160.00 OP

01/22/2007 JBALINAN 00000054 10691895

02 FC:1806 180.00 OP

**payment of the appropriate fee**, the Applicants elect to prosecute the invention of **Group IV** (Claims 56-61, in part, 66-69, and 70-74, in part), drawn to a pharmaceutical composition comprising a nonbridged aminocyclohexane derivative, of the Restriction Requirement.

The Examiner may withdraw the non-elected subject matter, without prejudice to its rejoinder during later examination and/or prosecution in a Divisional Application.

Finally, with the instant Response, the Applicants also submit an Information Disclosure Statement which, it is respectfully submitted, should materially advance and accelerate the prosecution of the above-identified application. It is respectfully requested that the information be expressly considered during the prosecution of this application and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

As will be noted, this Information Disclosure Statement calls a number of references, which might be considered relevant, to the attention of the Examiner. The fact that these references are in fact "Prior Art" is, however, not admitted.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR § 1.98 and the Examiner is respectfully requested to consider the listed references.